Hegi-Johnson, Fiona http://orcid.org/0000-0002-4543-8802
Rudd, Stacey
Hicks, Rodney J. http://orcid.org/0000-0002-0758-0824
De Ruysscher, Dirk
Trapani, Joseph A.
John, Thomas
Donnelly, Paul http://orcid.org/0000-0001-5373-0080
Blyth, Benjamin
Hanna, Gerard http://orcid.org/0000-0003-1003-5138
Everitt, Sarah
Roselt, Peter
MacManus, Michael P. http://orcid.org/0000-0002-0900-5815
Article History
Received: 8 June 2021
Accepted: 24 February 2022
First Online: 7 April 2022
Competing interests
: F.H.J.: Clinical Trial Funding, Honoraria and Advisory Boards Astra Zeneca. R.J.H.: Stockholder in Telix Pharmaceuticals. P.S.D.: Received research funding from Clarity Pharmaceuticals and Telix Pharmaceuticals. The University of Melbourne has licensed Intellectual Property where P.S.D. is listed as an inventor to Clarity Pharmaceuticals and Telix Pharmaceuticals. Serves on the Scientific Advisory Board and has a financial interest in Clarity Pharmaceuticals. M.P.M.: Clinical trial funding Varian Medical Systems. The remaining authors declare no competing interests.